Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.
Exciting New Treatment Updates Are on the Horizon for Advanced RCC
Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.
Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
Toripalimab Combo Receives Chinese Approval for Advanced RCC
Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.
Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Comparable Findings in White and Black Populations for ICI Use in Metastatic RCC
Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.
Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer
Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.